Literature DB >> 6831407

Effects of acivicin and dipyridamole on hepatoma 3924A cells.

Y S Zhen, M S Lui, G Weber.   

Abstract

Dipyridamole inhibited the incorporation of cytidine, thymidine, uridine, and guanosine in rat hepatoma 3924A cells with 50% inhibitory concentrations of 0.2 to 0.5 microM. For deoxycytidine, the 50% inhibitory concentration was about 100 times higher (23.8 microM). Addition of a combination of cytidine, deoxycytidine, and guanosine, at an optimal concentration of 80 microM each, protected the hepatoma cells from the growth-inhibitory action of the antiglutamine drug, acivicin. The protection provided by the nucleosides was blocked by dipyridamole (6 microM), but not by nitrobenzylthionosine (30 microM). The effect on cell survival of graded concentrations of 0.25 to 1.75 microM acivicin plus dipyridamole (5 microM) and 80 microM concentrations each of cytidine, deoxycytidine, and guanosine was investigated. At an acivicin concentration of 1.75 microM, survivals in the different groups were: (a) acivicin alone, 1%; (b) acivicin plus dipyridamole, 1%; (c) acivicin plus nucleosides, 78%; and (d) acivicin plus nucleosides plus dipyridamole, 3%. Acivicin and dipyridamole were cytotoxic for hepatoma 3924A cells with 50% inhibitory concentrations of 0.5 and 20.3 microM, respectively, as measured by clonogenic assay.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831407

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Expression of key enzymes of purine and pyrimidine metabolism in a hepatocyte-derived cell line at different phases of the growth cycle.

Authors:  D Mayer; Y Natsumeda; T Ikegami; M Faderan; M Lui; J Emrani; M Reardon; E Oláh; G Weber
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  A study of deoxyribonucleotide metabolism and its relation to DNA synthesis. Supercomputer simulation and model-system analysis.

Authors:  F Heinmets; R H Leary
Journal:  Cell Biophys       Date:  1991-06

3.  Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.

Authors:  S S Cao; Y S Zhen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Potentiation of cytotoxicity of mitoxantrone toward CHO-K1 cells in vitro by dipyridamole.

Authors:  P B Desai; R Sridhar
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

Review 5.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  Differential sensitivity of RSVts (temperature-sensitive Rous-sarcoma virus)-infected rat kidney cells to nucleoside antibiotics at permissive and non-permissive temperatures.

Authors:  Y Uehara; M Hasegawa; M Hori; H Umezawa
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

7.  Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.

Authors:  S Cabral; S Leis; L Bover; M Nembrot; J Mordoh
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.

Authors:  J Su; Y C Zhen; C Q Qi; J L Hu
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.

Authors:  H N Jayaram; K Murayama; K Pillwein; W Zhen; G Weber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Interaction of [3H]dipyridamole with the nucleoside transporters of human erythrocytes and cultured animal cells.

Authors:  C Woffendin; P G Plagemann
Journal:  J Membr Biol       Date:  1987       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.